title: A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.
authors.forename: Greetta
authors.initials: G
authors.lastname: Joensuu
authors.forename: Timo
authors.initials: T
authors.lastname: Joensuu
authors.forename: Nina
authors.initials: N
authors.lastname: Nupponen
authors.forename: Mirja
authors.initials: M
authors.lastname: Ruutu
authors.forename: Juhani
authors.initials: J
authors.lastname: Collan
authors.forename: Sari
authors.initials: S
authors.lastname: Pesonen
authors.forename: Akseli
authors.initials: A
authors.lastname: Hemminki
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000077156:Gefitinib; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000628:therapy*; D011799:Quinazolines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D017430:Prostate-Specific Antigen; D000077156:Gefitinib